|
Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating |
Bank Loan Ratings | 20.70 | ACUITE BB- | Reaffirmed | Issuer not co-operating* | - |
Bank Loan Ratings | 4.05 | - | ACUITE A4+ | Reaffirmed | Issuer not co-operating* |
Total Outstanding Quantum (Rs. Cr) | 24.75 | - | - |
Rating Rationale |
Acuite has reaffirmed the long term rating of ‘ACUITE BB-’ (read as ACUITE Double B minus)' and the short term rating of ‘ACUITE A4+’ (read as ACUITE A four plus) on the Rs.24.75 crore bank facilities of Symbiosis Pharmaceuticals Private Limited (SPPL). The rating continues to be flagged as “Issuer Not-Cooperating” and is based on best available information.
|
About the Company |
Symbiosis Pharmaceuticals Private Limited (SPPL) was incorporated at Kala Amb, Himanchal Pradesh, in the year 2003 by Mr. V.D Gupta and Mr. Jagbir Singh. The company is involved in the manufacturing of medicine in various forms like Soft gelatine, tablets, tubes, drops etc. The company’s manufacturing unit is spread on 20000 sq. meter land area covering about 150000 sq. ft in Kala Amb, Himanchal Pradesh.
|
About the Group |
Symbiosis Group was incorporated in the year 2003 by Mr. V.D Gupta and Mr. Jagbir Singh. The group includes Symbiosis Pharmaceuticals Private Limited and Sai Tech Medicare Private Limited. Saitech Medicare Private Limited was established in the year 2008 by Mr. V.D Gupta and Mr. Jagbir Singh at Kala Amb, Himanchal Pradesh. The company is involved in the manufacturing of Allopathic Tablets, Capsules, Liquid Syrup, Ointment, Injectable etc. The company is situated at Kala Amb, Himanchal Pradesh.
|
Non-cooperation by the issuer/borrower: |
Acuité has been requesting for data, information and undertakings from the rated entity for conducting surveillance & review of the rating. However, the issuer/borrower failed to submit such information before the due date. Acuité believes that information risk is a critical component in such ratings, and noncooperation by the issuer along with unwillingness to provide information could be a sign of potential deterioration in its overall credit quality. This rating is, therefore, being flagged as “Issuer not-cooperating”, in line with prevailing SEBI regulations and Acuité’s policies.
|
Limitation regarding information availability: |
The rating is based on information available from sources other than the issuer/borrower (in the absence of information provided by the issuer/borrower). Acuité endeavoured to gather information about the entity / industry from the public domain. Therefore, Acuité cautions lenders and investors regarding the use of such information, on which the indicative credit rating is based.
|
Rating Sensitivity |
No information provided by the issuer / available for Acuité to comment upon.
|
Material Covenants |
Not Aplplicable.
|
Liquidity Position |
No information provided by the issuer / available for Acuité to comment upon.
|
Outlook |
Not Applicable.
|
Other Factors affecting Rating |
Not Applicable.
|
Particulars | Unit | FY 22 (Actual) | FY 21 (Actual) |
Operating Income | Rs. Cr. | 260.74 | 215.28 |
PAT | Rs. Cr. | 3.35 | 3.10 |
PAT Margin | (%) | 1.28 | 1.44 |
Total Debt/Tangible Net Worth | Times | 1.06 | 0.97 |
PBDIT/Interest | Times | 2.43 | 2.43 |
Status of non-cooperation with previous CRA |
Not Applicable.
|
Any other information |
Acuité is yet to receive the latest No Default Statement (NDS) from the rated entity, despite repeated requests and follow-ups.
|
Applicable Criteria |
• Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm • Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm • Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm |
Note on Complexity Levels of the Rated Instrument |
In order to inform the investors about complexity of instruments, Acuité has categorized such instruments in three levels: Simple, Complex and Highly Complex. Acuite’ s categorisation of the instruments across the three categories is based on factors like variability of the returns to the investors, uncertainty in cash flow patterns, number of counterparties and general understanding of the instrument by the market. It has to be understood that complexity is different from credit risk and even an instrument categorized as 'Simple' can carry high levels of risk. For more details, please refer Rating Criteria “Complexity Level Of Financial Instruments” on www.acuite.in.
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
|
|
Contacts |
Analytical | Rating Desk |
About Acuité Ratings & Research |
Acuité Ratings & Research Limited | www.acuite.in |